Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders
Autore:
Posey, DJ; Guenin, KD; Kohn, AE; Swiezy, NB; McDougle, CJ;
Indirizzi:
Indiana Univ, Sch Med, Dept Psychiat, Sect Child & Adolescent Psychiat, Indianapolis, IN USA Indiana Univ Indianapolis IN USA olescent Psychiat, Indianapolis, IN USA
Titolo Testata:
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
fascicolo: 3, volume: 11, anno: 2001,
pagine: 267 - 277
SICI:
1044-5463(200123)11:3<267:ANOSOM>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOUBLE-BLIND; FLUOXETINE TREATMENT; BEHAVIORAL SYMPTOMS; MAJOR DEPRESSION; ADULTS; CHILDREN; HALOPERIDOL; PLACEBO; RISPERIDONE; FENFLURAMINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: McDougle, CJ James Whitcomb Riley Hosp Children, 702 Barnhill Dr,Room 3701, Indianapolis, IN 46202 USA James Whitcomb Riley Hosp Children 702 Barnhill Dr,Room 3701 Indianapolis IN USA 46202
Citazione:
D.J. Posey et al., "A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders", J CH AD PSY, 11(3), 2001, pp. 267-277

Abstract

Objective: The aim of this study was to conduct a naturalistic, open-labelexamination of the efficacy and tolerability of mirtazapine (a medication with both serotonergic and noradrenergic properties) in the treatment of associated symptoms of autism and other pervasive developmental disorders (PDDs). Methods: Twenty-six subjects (5 females, 21 males; ages 3.8 to 23.5 years;mean age 10.1 +/- 4.8 years) with PDDs (20 with autistic disorder, 1 with Asperger's disorder, 1 with Rett's disorder, and 4 with PDDs not otherwise specified were treated with open-label mirtazapine (dose range, 7.5-45 mg daily; mean 30.3 +/- 12.6 mg daily). Twenty had comorbid mental retardation,and 17 were taking concomitant psychotropic medications. At endpoint, subjects' primary caregivers were interviewed using the Clinical Global Impressions (CGI) scale, the Aberrant Behavior Checklist, and a side-effect checklist. Results: Twenty-five of 26 subjects completed at least 4 weeks of treatment (mean 150 +/- 103 days). Nine of 26 subjects (34.6%) were judged responders ("much improved" or "very much improved" on the CGI) based on improvement in a variety of symptoms including aggression, self-injury, irritability,hyperactivity, anxiety, depression, and insomnia. Mirtazapine did not improve core symptoms of social or communication impairment. Adverse effects were minimal and included increased appetite, irritability, and transient sedation. Conclusions: Mirtazapine was well tolerated but showed only modest effectiveness for treating the associated symptoms of autistic disorder and other PDDs.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 18:44:34